Aardvark Therapeutics (AARD) Total Non-Current Liabilities (2024 - 2025)
Aardvark Therapeutics (AARD) reported Total Non-Current Liabilities of $10.5 million for Q4 2025, up 96.5% on a YoY basis from $5.4 million in Q4 2024, and down 2.8% sequentially from $10.9 million in Q3 2025.
Aardvark Therapeutics (AARD) Total Non-Current Liabilities (2024 - 2025) Analysis & Trends
Aardvark Therapeutics (AARD) has 2 years of Total Non-Current Liabilities data on file, last reported at $10.5 million in Q4 2025.
- For the quarter ending Q4 2025, Total Non-Current Liabilities rose 96.5% year-over-year to $10.5 million; the trailing twelve-month figure through Dec 2025 stood at $10.5 million (up 96.5% YoY), and the FY2025 full-year result was $10.5 million, up 96.5% from the prior year.
- Total Non-Current Liabilities slipped to $10.5 million in Q4 2025, from $10.9 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $10.9 million in Q3 2025 to a low of $5.4 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Aardvark Therapeutics | 139.40 Mn | 19.44 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 10.55 Mn |
| Sep 30, 2025 | 10.85 Mn |
| Jun 30, 2025 | 10.54 Mn |
| Mar 31, 2025 | 6.31 Mn |
| Dec 31, 2024 | 5.37 Mn |